152 related articles for article (PubMed ID: 19446274)
1. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.
Rudick RA; Polman CH
Lancet Neurol; 2009 Jun; 8(6):545-59. PubMed ID: 19446274
[TBL] [Abstract][Full Text] [Related]
2. Established disease-modifying treatments in relapsing-remitting multiple sclerosis.
Oh J; O'Connor PW
Curr Opin Neurol; 2015 Jun; 28(3):220-9. PubMed ID: 25923124
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response.
Hesse D; Krakauer M; Lund H; Søndergaard HB; Langkilde A; Ryder LP; Sorensen PS; Sellebjerg F
Neurology; 2010 May; 74(18):1455-62. PubMed ID: 20439848
[TBL] [Abstract][Full Text] [Related]
4. Current and future treatments for relapsing-remitting multiple sclerosis.
Birnbaum G
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):214-25. PubMed ID: 20205055
[TBL] [Abstract][Full Text] [Related]
5. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
6. Emerging oral drugs for relapsing-remitting multiple sclerosis.
Gasperini C; Ruggieri S
Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
[TBL] [Abstract][Full Text] [Related]
7. B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
Rovituso D; Heller S; Schroeter M; Kleinschnitz C; Kuerten S
J Neuroimmunol; 2014 Jul; 272(1-2):86-90. PubMed ID: 24814390
[TBL] [Abstract][Full Text] [Related]
8. Current evidence and therapeutic strategies for multiple sclerosis.
Wingerchuk DM
Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
[TBL] [Abstract][Full Text] [Related]
9. Definitions of breakthrough disease and second-line agents.
Marriott JJ; O'Connor PW
Neurol Clin; 2011 May; 29(2):411-22. PubMed ID: 21439450
[TBL] [Abstract][Full Text] [Related]
10. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
11. Emerging oral therapies for multiple sclerosis.
Cohen BA; Rieckmann P
Int J Clin Pract; 2007 Nov; 61(11):1922-30. PubMed ID: 17784852
[TBL] [Abstract][Full Text] [Related]
12. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
14. [Update on current care guidelines: multiple sclerosis].
Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898
[TBL] [Abstract][Full Text] [Related]
15. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting.
Karussis D; Biermann LD; Bohlega S; Boiko A; Chofflon M; Fazekas F; Freedman M; Gebeily S; Gouider R; Havrdova E; Jakab G; Karabudak R; Miller A;
Eur J Neurol; 2006 Jan; 13(1):61-71. PubMed ID: 16420394
[TBL] [Abstract][Full Text] [Related]
16. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.
Schwarz M; Spector L; Gortler M; Weisshaus O; Glass-Marmor L; Karni A; Dotan N; Miller A
J Neurol Sci; 2006 May; 244(1-2):59-68. PubMed ID: 16480743
[TBL] [Abstract][Full Text] [Related]
18. Predicting and preventing the future: actively managing multiple sclerosis.
Hutchinson M
Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
20. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
Stüve O; Leussink VI; Fröhlich R; Hemmer B; Hartung HP; Menge T; Kieseier BC
Arch Neurol; 2009 Feb; 66(2):259-61. PubMed ID: 19204165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
